Med24
Clinical Medicine 6. 11. 2026 • 2 min read • MedPage Today

Gene Therapy Under Scrutiny After Nine Tumor Reports

Drugmaker Novartis acknowledged Thursday that there have been nine reports of tumors in children treated with its gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA). Two of the tumor cases were...

Gene Therapy Under Scrutiny After Nine Tumor Reports

Novartis acknowledged nine reports of tumors in children treated with onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA). Two of the tumor cases were linked to the drug, with evidence of vector DNA integration into the patients’ DNA observed in both instances. Both patients continue to be monitored.

Sponsored content

Tumor Reports and Investigation

The remaining seven cases have not been detailed regarding timing or identification. SMA is caused by reduced levels of the survival motor neuron (SMN) protein due to deletions or mutations in the SMN1 gene. Zolgensma, an AAV vector-based gene therapy, was approved in 2019 for pediatric patients under 2 years with bi-allelic SMN1 mutations. SMA Europe acknowledged the reports and stated that regulatory authorities are actively involved in assessing the evidence and determining necessary steps. The Muscular Dystrophy Association (MDA) is seeking additional information and reviewing data with experts. A 2023 case report described a 16-month-old boy with SMA who was diagnosed with an epithelioid neoplasm of the spinal cord 14 months after receiving Zolgensma; the finding was considered inconclusive. A 2025 case report detailed a pilocytic astrocytoma in a child with SMA treated with Zolgensma, with molecular analysis suggesting tumorigenesis was causally independent of the gene therapy. Earlier this year, researchers identified vector integration in a brain tumor in a 5-year-old boy with severe mucopolysaccharidosis type I (Hurler syndrome) who received another AAV gene therapy. More than 6,000 patients have been treated with Zolgensma in clinical trials, managed access programs, and commercial treatment. Novartis continually evaluates new safety information and assesses all reported cases. The tumor reports are not the first controversy involving Zolgensma, with the FDA previously criticizing AveXis over data manipulation.

Original Scientific Source
MedPage Today
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement